H Kupper
10 Papers
86 Citations
H Kupper is an academic researcher. The author has contributed to research in topics: Adalimumab & Placebo. The author has an hindex of 8, co-authored 10 publications.
Chat about Author
Papers
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study
Konrad Reinhart,Thilo Menges,Bengt Gårdlund,JH Zwaveling,Mark Smithes,Jean Louis Vincent,Jose M. Tellado,Antonio Salgado-Remigio,Reuven Zimlichman,Stuart Withington,Klaus Tschaikowsky,Rainer Brase,Pierre Damas,H Kupper,Joachim Kempeni,Juergen Eiselstein,Martin Kaul +16 more
TL;DR: The IL-6 immunostrip test identified two distinct sepsis populations with significantly different mortality rates and a small absolute reduction in mortality rate was found in the afelimomab-treated patients.
266
•Journal Article
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
Alfons A den Broeder,Leo B A van de Putte,Rolf Rau,M. Schattenkirchner,Piet L. C. M. van Riel,Oliver Sander,Christina Binder,Helmut Fenner,Yvonne Bankmann,Raja Velagapudi,Joachim Kempeni,H Kupper +11 more
TL;DR: Treatment with the fully human Mab adalimumab was safe and well tolerated when administered as a single intravenous injection at doses up to 10 mg/kg, and was associated with a clinically significant improvement in the signs and symptoms of active RA.
223
Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate.
Rolf Rau,S. Simianer,P.L.C.M. van Riel,L.B.A. van de Putte,Klaus Krüger,M. Schattenkirchner,C.F. Allaart,Ferdinand C. Breedveld,Joachim Kempeni,K. Beck,H Kupper +10 more
TL;DR: Subcutaneously administered adalimumab appeared to provide a response that was as great, as rapid, and as enduring as that with i.v. or s.c.c., and significantly improved the signs and symptoms of RA compared with MTX alone.
47
OP0062 The fully human anti-tnf antibody adalimumab (d2e7) in combination with methotrexate (mtx) in the treatment of active rheumatoid arthritis: results of a 2-year study
F. C. Breedveld,Cornelia F Allaart,Rolf Rau,G. Herborn,Siegfried Wassenberg,E.J.A. Kroot,P.L.C.M. van Riel,L. B. A. Van De Putte,C Böger,M. Schattenkirchner,Joachim Kempeni,K. Beck,H Kupper +12 more
TL;DR: Repeated subcutaneous injections of 1 mg/kg adalimumab (D2E7) over a period of two years showed sustained efficacy and were well tolerated when given in combination with stable standard doses of MTX to patients with active rheumatoid arthritis.
24
Ut6 improvement in health utility among rheumatoid arthritis (ra) patients treated with adalimumab (d2e7), a fully human anti-tnf monoclonal antibody
TL;DR: This study suggests that the Torrance transformation of the rating scale or EuroQoL from patient reports are feasible and robust instruments for assessing patient preferences regarding quality of life and can be used in costeffectiveness analyses in studies of patients with chronic hepatitis C.
10